老年不可切除肝细胞癌患者仑伐替尼治疗后的肝功能。

Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.

机构信息

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

出版信息

Anticancer Res. 2021 Apr;41(4):2025-2032. doi: 10.21873/anticanres.14970.

DOI:10.21873/anticanres.14970

PMID:33813409

Abstract

BACKGROUND

The age of patients with advanced hepatocellular carcinoma (HCC) eligible for molecular-targeted drug treatment is increasing. We assessed liver function after lenvatinib administration according to age in patients with advanced HCC.

PATIENTS AND METHODS

In this retrospective, multicenter, observational study, we reviewed the records of patients with HCC who received lenvatinib treatment (March 2018-March 2020). Liver function was measured using the Albumin-Bilirubin Index (ALBI).

RESULTS

Of 119 patients, with a median age of 72.0 years, median overall survival was 15.3 months. Overall survival was significantly better in the group which maintained liver function (p=0.02). Older age (≥72 years) was associated with liver-function deterioration within 8 weeks (odds ratio=2.47, 95% confidence interval=1.06-5.75, p=0.035). The ALBI score was significantly higher in the older group at 4 and 8 weeks after lenvatinib administration.

CONCLUSION

Lenvatinib administration was more likely to adversely affect liver function in older patients; dose adjustment should be considered in such patients.

摘要

背景

适合接受分子靶向药物治疗的晚期肝细胞癌（HCC）患者的年龄正在增加。我们根据年龄评估了晚期 HCC 患者接受仑伐替尼治疗后的肝功能。

患者和方法

在这项回顾性、多中心、观察性研究中，我们回顾了接受仑伐替尼治疗的 HCC 患者的记录（2018 年 3 月至 2020 年 3 月）。使用白蛋白-胆红素指数（ALBI）测量肝功能。

结果

在 119 名患者中，中位年龄为 72.0 岁，中位总生存期为 15.3 个月。维持肝功能的组总生存期明显更好（p=0.02）。8 周内肝功能恶化与年龄较大（≥72 岁）相关（比值比=2.47，95%置信区间=1.06-5.75，p=0.035）。仑伐替尼给药后 4 周和 8 周，老年组的 ALBI 评分明显更高。